Genentech

OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, February 15, 2024

BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H.

Key Points: 
  • BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H.
  • as Chief Medical Officer.
  • “Sam’s leadership experience and expertise in oncology drug development will be invaluable as we advance our portfolio,” said Nick Saccomano, Ph.D., Chief Executive Officer of OnKure.
  • Dr. Agresta also served as a Director and Chief Medical Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the Phase 1 and 2 developments of the PI3Ky inhibitor, IPI-549.

Firefly Bio Debuts With $94 Million Series A Financing

Retrieved on: 
Thursday, February 15, 2024

Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.

Key Points: 
  • Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng Capital and with participation from Eli Lilly & Company.
  • Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs).
  • Firefly was incubated in close collaboration with scientists at Versant’s Ridgeline Discovery Engine in the Basel Technology Park.
  • “At Firefly, we’ve assembled a unique talent base and platform to significantly advance this promising field,” said Jerel Davis, Ph.D., Managing Director at Versant and a Firefly board member.

Merit Medicine Announces $2M Seed Round to Transform Employer-Sponsored Healthcare with AI-Powered Risk Predictions

Retrieved on: 
Thursday, February 15, 2024

Founded in 2022, Merit Medicine seeks to bring AI insights to the often-opaque employer-sponsored health insurance market.

Key Points: 
  • Founded in 2022, Merit Medicine seeks to bring AI insights to the often-opaque employer-sponsored health insurance market.
  • Employers who self-fund their employees’ health plans face an era of rapidly escalating healthcare costs.
  • “And employer contributions to healthcare now make up roughly $600 billion of annual healthcare spending in the United States.
  • The team's domain experience also stood out with experience in drug pricing, market access, and healthcare data analytics.”

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on: 
Thursday, February 15, 2024

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points: 
  • “We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
  • Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
  • Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
  • “I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Retrieved on: 
Wednesday, February 14, 2024

FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.

Key Points: 
  • The team is now set and focused on executing our phase 3 program to turn our science into a reality for patients suffering from diabetic retinopathy, the leading cause of blindness in America.
  • I'm excited to work alongside such a talented team and together to take on significant unmet medical needs with compelling science.”
    Dr. Jayagopal added, “I am excited to join the talented Ocuphire team that has a successful track record in drug development and execution.
  • Prior to joining Ocuphire, he served as the Chief Scientific Officer of Opus Genetics.
  • In this role he had scientific and clinical leadership responsibility for Opus’ retinal gene therapy portfolio, including management of discovery, manufacturing, nonclinical development, and clinical development functions.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Retrieved on: 
Thursday, February 8, 2024

Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.

Key Points: 
  • Wet AMD poses a particularly severe threat to vision, necessitating treatment with biologic therapies administered in four to twelve-week intervals.
  • However, the current treatment landscape often burdens elderly patients with high treatment frequencies, impacting their ability to attend all appointments.
  • Spherix Global Insights conducted an in-depth analysis through its RealTime Dynamix™ report series, delving into the evolving perceptions of ophthalmologists (n=101) regarding approved therapies for wet AMD.
  • In January 2024, ophthalmologists were surveyed on their preferred biologic treatment for wet AMD among other topics.

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

Retrieved on: 
Wednesday, February 7, 2024

FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Amy Burroughs as chief executive officer (CEO), effective immediately.

Key Points: 
  • FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Amy Burroughs as chief executive officer (CEO), effective immediately.
  • Ms. Burroughs will also join the Terns board of directors.
  • “We are pleased to welcome Amy to the Terns team to lead the company in its next stage of growth,” said David Fellows, chairman of the board of directors.
  • Ms. Burroughs earned an M.B.A. from Harvard Business School, where she graduated as a Baker Scholar, and a B.A.

Ted Love, MD, Joins Gilead Sciences’ Board of Directors

Retrieved on: 
Thursday, February 1, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors.
  • Dr. Love is currently chair of the Board of Directors of the Biotechnology Innovation Organization and serves on the Boards of Directors of Royalty Pharma and Structure Therapeutics.
  • “We are delighted to welcome Ted Love to the Gilead Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences.
  • Ted will be a valuable addition to the Gilead Board as we continue to expand our impact on patients and communities worldwide.”

Abdera Therapeutics Expands Management Team and Board of Directors

Retrieved on: 
Tuesday, January 30, 2024

“We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.

Key Points: 
  • “We are thrilled to welcome Philippe and Eric to Abdera,” said Lori Lyons-Williams, president and chief executive officer.
  • I am excited to join the Abdera team and help build a differentiated pipeline.”
    Mr. Dobmeier is an executive and board member with more than 20 years of experience in the biotechnology industry.
  • He currently serves on the boards of Structure Therapeutics and Atara Therapeutics.
  • “I look forward to working with the rest of the board and leadership team as Abdera prepares to transition into a clinical-stage company and enter its next phase of growth.”